Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLN-121
- Development stage
- Phase 1
- Lead developer
- Treeline Biosciences
01
Overview
TLN-121 is an investigational anti-cancer drug being evaluated for the treatment of relapsed or refractory non-Hodgkin lymphomas. In clinical studies, it is being assessed both as a single agent and in combination with other anti-lymphoma treatments. The primary indications under investigation include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) (grades 1-3b), and selected subtypes of peripheral T-cell lymphoma (PTCL) after prior lines of therapy. The precise mechanism of action, molecular target, and drug modality have not been publicly disclosed in current available sources but it is described as a targeted therapy aiming to selectively attack cancer cells.[1][3][4][10]
- Other names
- TLN-121TLN121TLN 121
Beyond the preview
Go deeper on TLN-121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLN-121.